Sign Up

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the "Offering") of 40,000,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares from the Company (the "Shares"). The Shares were sold at a public offering price of $5.75 per share.

In addition, Anteris today announced the closing of its previously announced sale, in a private placement (the "Private Placement"), of 15,652,173 shares of common stock to Medtronic plc (through a wholly owned subsidiary) at a price of $5.75 per share.

The gross proceeds to the Company from the Offering and the Private Placement were approximately $320 million, prior to deducting underwriting discounts and commissions in the Offering, placement agent fees in the Private Placement, and estimated expenses of each of the Offering and the Private Placement.

Barclays, Wells Fargo Securities and Cantor acted as joint book-running managers for the Offering. Barrenjoey Markets Pty Limited acted as financial advisor in connection with the Offering to investors in Asia-Pacific and certain other jurisdictions outside of the United States and Canada. Wells Fargo Securities acted as sole placement agent in connection with the private placement of Anteris' shares to Medtronic.

Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from the Private Placement, to support the next stage of growth and advance execution of the Company's clinical strategy. This includes ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve ("DurAVR® THV") global pivotal trial for patients with severe aortic stenosis (the "PARADIGM Trial") and expansion of manufacturing capabilities. In addition, a portion of the proceeds is expected to fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes determined from ...